Physician profile
Patrick W Tester
NPI 1649263617
$917.50
in general payments reported to CMS, 2019-2025
21 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $144 · 2021: $185 · 2022: $77.66 · 2023: $149 · 2024: $93.34 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $364.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $266.28 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $160.57 | 2021-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $115.33 | 2021-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $58.23 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.04 | 2019 | |
| Lilly USA, LLC | $28.75 | 2021-2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $28.42 | 2020 | |
| Glaxosmithkline, LLC. | $27.30 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $20.75 | 2021 | |
| Mylan Specialty L.P. | $19.28 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.99 | 2020 | |
| Astellas Pharma US INC | $18.74 | 2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $16.58 | 2025 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals Lp | $15.94 | 2025 | Breztri |
| Arbor Pharmaceuticals, INC. | $15.33 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14.20 | 2019 | |
| Abbvie INC. | $13.04 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.39 | 2020 | |
| Merck Sharp & Dohme LLC | $12.29 | 2021 | |
| Pfizer INC. | $12.18 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Tester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.